Back to search

Article

Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in mice

2022-12-21

Abstract excerpt

Obesity is rapidly increasing within the global population and is one of the leading causes of chronic diseases, including type 2 diabetes (T2D), non-alcoholic fatty liver disease, and cardiovascular diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as promising therapeutic agents for treating T2D and obesity. However, the route of administration of the GLP-1R agonists is currently by injec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8a441cd9-ab00-5d78-ada1-93d53edeb3e1
DOI
10.1101/2022.12.21.521368
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in miceDOI 10.1101/2022.12.21.521368
Select a neighboring publication to make it the new centre.